Stifel Financial
NTLA icon

Stifel Financial’s Intellia Therapeutics NTLA Stock Holding History

Stifel Financial’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.2M Buy
1,014,387
+1,681
+0.2% +$23.5K 0.01% 747
2026
Q1 		$13M Buy
1,012,706
+81,315
+9% +$1.04M 0.01% 833
2025
Q4 		$8.37M Buy
931,391
+152,875
+20% +$2.1M 0.01% 1049
2025
Q3 		$13.4M Sell
778,516
-6,518
-0.8% -$80.3K 0.01% 805
2025
Q2 		$7.36M Sell
785,034
-4,628
-0.6% -$38K 0.01% 1043
2025
Q1 		$5.61M Buy
789,662
+391,901
+99% +$3.96M 0.01% 1124
2024
Q4 		$4.64M Buy
397,761
+303,151
+320% +$4.73M ﹤0.01% 1247
2024
Q3 		$1.94M Buy
94,610
+3,102
+3% +$71.5K ﹤0.01% 1794
2024
Q2 		$2.05M Buy
91,508
+7,416
+9% +$177K ﹤0.01% 1707
2024
Q1 		$2.31M Buy
84,092
+15,569
+23% +$432K ﹤0.01% 1615
2023
Q4 		$2.09M Buy
68,523
+18,734
+38% +$538K ﹤0.01% 1639
2023
Q3 		$1.57M Buy
49,789
+6,387
+15% +$248K ﹤0.01% 1753
2023
Q2 		$1.77M Buy
43,402
+12,617
+41% +$512K ﹤0.01% 1715
2023
Q1 		$1.15M Buy
30,785
+430
+1% +$16.9K ﹤0.01% 1954
2022
Q4 		$1.06M Buy
30,355
+5,070
+20% +$241K ﹤0.01% 1962
2022
Q3 		$1.42M Buy
25,285
+1,028
+4% +$63.8K ﹤0.01% 1702
2022
Q2 		$1.26M Buy
24,257
+6,088
+34% +$309K ﹤0.01% 1827
2022
Q1 		$1.32M Sell
18,169
-1,605
-8% -$136K ﹤0.01% 1920
2021
Q4 		$2.34M Sell
19,774
-349
-2% -$43.7K ﹤0.01% 1501
2021
Q3 		$2.7M Sell
20,123
-3,213
-14% -$486K ﹤0.01% 1378
2021
Q2 		$3.78M Sell
23,336
-5,201
-18% -$405K 0.01% 1173
2021
Q1 		$2.29M Buy
28,537
+10,477
+58% +$703K ﹤0.01% 1438
2020
Q4 		$982K Buy
+18,060
New +$656K ﹤0.01% 1855
2018
Q4 		– Sell
-8,125
Closed -$234K – 2768
2018
Q3 		$234K Buy
+8,125
New +$236K ﹤0.01% 2490

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return

Stifel Financial's NTLA Position: Q2 2026 in Review

Stifel Financial increased its Intellia Therapeutics (NTLA) stake by 0.17% in Q2 2026, buying an estimated $23.5K and bringing the position to 1,014,387 shares worth $17.2M. The position accounts for 0.01% of the portfolio, ranked #747.

Stifel Financial first reported a position in NTLA in Q3 2018 and has held it in 24 quarters since. 329 funds tracked by Wall St. Rank hold NTLA as of Q2 2026.

  • Stifel Financial held 1,014,387 shares of Intellia Therapeutics worth $17.2M as of Q2 2026.
  • Stifel Financial bought 1,681 Intellia Therapeutics shares in Q2 2026, an estimated $23.5K.
  • Intellia Therapeutics made up 0.01% of Stifel Financial's portfolio in Q2 2026, its #747 holding.
  • Stifel Financial first reported a position in Intellia Therapeutics in Q3 2018 and has held it in 24 quarters since.
  • 329 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2026.

Based on Stifel Financial's 13F filing for Q2 2026, filed 12 Aug 2026.